Cargando…
Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women
Progressive supranuclear palsy (PSP) is a pure tauopathy, implicating davunetide, enhancing Tau-microtubule interaction, as an ideal drug candidate. However, pooling patient data irrespective of sex concluded no efficacy. Here, analyzing sex-dependency in a 52 week-long- PSP clinical trial (involvin...
Autores principales: | Gozes, Illana, Shapira, Guy, Lobyntseva, Alexandra, Shomron, Noam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579238/ https://www.ncbi.nlm.nih.gov/pubmed/37845254 http://dx.doi.org/10.1038/s41398-023-02618-9 |
Ejemplares similares
-
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy
por: Gold, Michael, et al.
Publicado: (2012) -
NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies
por: Ivashko-Pachima, Yanina, et al.
Publicado: (2019) -
NAP (Davunetide): The Neuroprotective ADNP Drug Candidate Penetrates Cell Nuclei Explaining Pleiotropic Mechanisms
por: Ganaiem, Maram, et al.
Publicado: (2023) -
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein
por: Magen, Iddo, et al.
Publicado: (2014) -
Zolpidem in Progressive Supranuclear Palsy
por: Dash, Sandip K.
Publicado: (2013)